Oncogene

Oncogene is a peer-reviewed journal published by Springer Nature under its Nature Portfolio imprint that covers the cellular and molecular biology of cancer, founded in 1987, and it holds a 2025 Journal Impact Factor of 9.1《癌基因》（Oncogene）是由（Springer Nature）旗下（Nature Portfolio）出版的同行评审期刊，覆盖癌症的细胞与分子生物学，1987 年创办，2025 年影响因子为 9.1。

Scope

• It publishes basic, clinical and translational research on the cellular and molecular biology of cancer, including resistance to cancer therapies and better approaches to improving survival该刊发表癌症细胞与分子生物学的基础、临床与转化研究，包括癌症治疗耐药性与改善生存的更好途径。^[1]
• The journal covers cellular oncogenes and their mechanisms of activation, together with the structure and function of the proteins they encode该刊涵盖细胞癌基因及其激活机制，以及其编码蛋白的结构与功能。
• Its remit takes in tumour suppressor genes, growth regulatory genes, cell cycle control, growth factors and receptors, and apoptosis其范围涉及抑癌基因、生长调控基因、细胞周期调控、生长因子与受体以及细胞凋亡。
• It also addresses the molecular oncology of human tumours and the oncogenes of the DNA and RNA tumour viruses该刊还涉及人类肿瘤的分子肿瘤学，以及（DNA）与（RNA）肿瘤病毒的癌基因。
• The journal seeks work that establishes new paradigms in the aetio-pathogenesis, diagnosis, treatment or prevention of cancers and in metastatic spread该刊寻求在癌症病因发病机制、诊断、治疗或预防以及转移扩散方面确立新范式的研究。
• It has a broad remit across the life sciences and biomedicine, from fundamental and theoretical work through to translational, applied and clinical research, including early and late phase clinical trials with biologic and translational endpoints该刊范围横跨生命科学与生物医学，从基础理论研究直到转化、应用与临床研究，包括具有生物标志与转化终点的早晚期临床试验。

History

• Oncogene was founded in 1987 by the Scientific and Medical Division of Macmillan Press in the United Kingdom《癌基因》于 1987 年由英国（Macmillan Press）的科学与医学部创办。
• From about 2002 it has been published by Nature Publishing Group, which is now part of the Nature Portfolio at Springer Nature自 2002 年前后起，该刊由（Nature Publishing Group）出版，该集团现为（Springer Nature）旗下（Nature Portfolio）的一部分。
• The journal carries 50 issues per year该刊每年出版 50 期。
• It is indexed in the Science Citation Index Expanded, Scopus, BIOSIS and Current Contents/Life Sciences, among other databases该刊被（Science Citation Index Expanded）、（Scopus）、（BIOSIS）与（Current Contents/Life Sciences）等数据库收录。
• Its Journal Impact Factor moved from 9.867 in 2021 and 8.756 in 2022 to 7.3 in 2024 and 9.1 in 2025其影响因子由 2021 年的 9.867 与 2022 年的 8.756 变为 2024 年的 7.3 与 2025 年的 9.1。
• It ranks in the first quartile of the genetics and heredity category, and its five-year Journal Impact Factor is 8.1该刊位居遗传学与遗传类第一四分位，其五年影响因子为 8.1。

Editors

• Georgios Giamas, Professor of Cancer Cell Signalling at the University of Sussex in the United Kingdom and at Zhejiang Chinese Medical University, became Editor-in-Chief on 1 January 2026（Georgios Giamas）为（University of Sussex）癌症细胞信号转导教授，并任职于（Zhejiang Chinese Medical University），于 2026 年 1 月 1 日出任主编。
• Joseph Kissil, who chairs the Department of Molecular Oncology at the Moffitt Cancer Center in the United States, serves as the other Editor-in-Chief and studies signal transduction pathways in cancer（Joseph Kissil）为美国（Moffitt Cancer Center）分子肿瘤学系主任，任另一位主编，从事癌症信号转导通路研究。
• Christopher N. Parris of Anglia Ruskin University in the United Kingdom is the Deputy Editor（Christopher N. Parris）来自英国（Anglia Ruskin University），任副主编。
• Reviewing Editors, described as among the most respected and accomplished individuals in their fields, cover areas from genetics and structural biology to function and mechanism审稿编辑被描述为其领域内最受尊敬与成就卓著者，覆盖从遗传学、结构生物学到功能与机制的各个方向。
• The journal is edited under the Nature Portfolio imprint of Springer Nature, and its editorial office oversees review and publication该刊由（Springer Nature）旗下（Nature Portfolio）编辑，其编辑部负责评审与出版。
• Oncogene publishes original research articles and commissioned review collections on selected themes in cancer biology《癌基因》发表原创研究论文，并就有代表性的癌症生物学主题组织邀约综述专辑。